GlassScriptPhysician profile
Laura L Redden
NPI 1699021105
$8,477.18
in general payments reported to CMS, 2019-2025
25 companies · $5,062 in 2025
The $5,062 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $1,134 · 2023: $863 · 2024: $1,162 · 2025: $5,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,454 · Consulting Fee: $2,415 · Travel and Lodging: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,453.65 |
| Consulting Fee | $2,415.00 |
| Travel and Lodging | $1,217.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $4,485.42 | 2022-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $740.89 | 2022-2025 | Farxiga, Lokelma, Wainua |
| Pfizer INC. | $503.10 | 2022-2025 | |
| Amgen INC. | $359.59 | 2021-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $310.20 | 2022-2025 | Amvuttra, Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $290.44 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $244.01 | 2021-2024 | Xarelto |
| Philips North America LLC | $229.00 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Novartis Pharmaceuticals Corporation | $215.96 | 2021-2025 | |
| Novo Nordisk INC | $163.08 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.43 | 2021-2025 | Jardiance |
| Abbott Laboratories | $152.72 | 2025 | Mitraclip |
| Actelion Pharmaceuticals US, INC. | $149.92 | 2021-2025 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $93.86 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.51 | 2024-2025 | Lifevest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $56.12 | 2022-2024 | Evkeeza |
| Bridgebio Pharma, INC. | $52.87 | 2025 | Attruby |
| Boston Scientific Corporation | $42.18 | 2023-2025 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $32.49 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $32.48 | 2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $27.43 | 2022 | |
| Impulse Dynamics (USA) INC. | $24.07 | 2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $16.43 | 2023 | |
| Amarin Pharma, INC. | $15.14 | 2021 | |
| Cvrx, INC. | $14.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Redden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.